Alector reports first quarter 2025 financial results and provides business update

Topline data from pivotal infront-3 phase 3 clinical trial of latozinemab in ftd-grn on track for q4 2025 completed enrollment in progress-ad phase 2 clinical trial of al101 in early alzheimer's disease continuing to pursue alector brain carrier programs, including the company's anti-amyloid beta antibody and its gcase enzyme replacement therapy extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments south san francisco, calif., may 08, 2025 (globe newswire) -- alector, inc. (nasdaq: alec), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates.
ALEC Ratings Summary
ALEC Quant Ranking